[The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
The incidence of heart failure is increasing and its prevalence is high, ranging from 1% to 2% in middle aged patients to more than 10% in older patients. Several pharmacologic approaches developed during the past 15 years, have had at least in clinical trials a significant impact on progression of heart failure mortality. The effect of ACE-inhibitors has been documented extensively during the last 15 years. They offered 15% decrease in hospitalization for moderate heart failure and, depending on the severity of the disease, produced a 16% to 31% reduction in mortality. Angiotensin receptor blockers provide unique pharmacological mechanism, and have demonstrated high tolerability in large trials. According to the new ACC/AHA guidelines for the evaluation and management of heart failure, the results of evidence based studies using ACE-inhibitor and angiotensin blocker therapies were analyzed by the author.
Kárpáti
Pál
P
Fovárosi Szent István Kórház I, Belgyógyászat, Budapest.
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D009203:Myocardial Infarction / Q000150:complications; D012084:Renin-Angiotensin System / Q000187:drug effects; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors